Abstract Details

Title Clinical Validation of a Handheld Assistive Device for Tremor

Topic Movement Disorders

Presentation(s) S53 - (-)

Poster/Presentation
Number 005

Objective

Background Essential Tremor (ET) causes action tremors that can severely limit a person's ability to eat, resulting in decreased quality of life. A compact, handheld, battery-powered device is presented that stabilizes a spoon when shaken by an unsteady hand. The device employs ACT technology to sense motion, detect whether the motion is tremor, and move the spoon to cancel tremor.

Design/Methods Eleven subjects (9M/2F) with ET performed three tasks (holding, eating, and transferring objects) using a spoon device with ACT turned on and off. Tremor amplitude during these tasks was measured using accelerometers embedded in the device. Tremor was rated clinically by a neurologist using the Fahn-Tolosa-Marin Tremor Rating Scale, and overall improvement was rated by the subject using the Clinical Global Impression Scale (CGI-S). Both subject and neurologist were blinded to whether the device was on or off.

Results With ACT turned on, tremor amplitude was reduced by an average of 72% in the holding task, 76% in the eating task, and 71% in the transferring task as measured with the accelerometer. There was significant improvement in tremor scores with ACT on compared to ACT off in the eating (1.18 ± 0.98 vs. 0.00 ± 0.45, p=0.003) and transferring (1.18 ± 0.75 vs. 0.27 ± 0.65, p=0.006) tasks, but not the holding task. CGI-S was also significantly improved with ACT on versus ACT off with eating (2.45 ± 1.51 vs. 4.27 ± 0.47, p=0.002) and transferring (2.45 ± 1.37 vs. 3.82 ± 1.47, p=0.04).

Conclusions The ACT assistive device can reduce tremor amplitude of a spoon when being used by individuals with ET. The tremor reduction is clinically evident and can make eating tasks easier, potentially improving an individual's quality of life.

Authors/Disclosures
Anupam Pathak, PhD (Google Inc) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Kelvin L. Chou, MD, FAAN (University of Michigan Health, Department of Neurology)	Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Accordant. Dr. Chou has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurocrine. Dr. Chou has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abbott. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerevance. Dr. Chou has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Advarra. The institution of Dr. Chou has received research support from NIH. The institution of Dr. Chou has received research support from Parkinson Study Group. The institution of Dr. Chou has received research support from Michael J Fox Foundation. The institution of Dr. Chou has received research support from Cerevance. Dr. Chou has received publishing royalties from a publication relating to health care. Dr. Chou has received publishing royalties from a publication relating to health care.
	No disclosure on file

��ɫ��

��ɫ��